Skip to content

Statera Biopharma, Inc.

CIK 0001318641

← back to feed
Revenue (TTM)
$2.67M
Q3 Nov 2022
Net Income (TTM)
−$27.31M
−742.2% YoY Q3 Nov 2022
EPS Diluted (TTM)
−$0.22
+376.2% YoY Q3 Nov 2022
Gross Margin
68.6%
Q3 Nov 2022
Operating Margin
-772.6%
Q3 Nov 2022
Net Margin
-1,021.6%
Q3 Nov 2022
Free Cash Flow (TTM)
−$7.79M
Q3 Nov 2022
Cash
$506.1K
Q3 Nov 2022
Total Debt
$0
Q3 Nov 2022
Shares Outstanding
54.66M sh
Q3 Nov 2022

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings